Livforsakringsbolaget Skandia Omsesidigt Lowers Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Livforsakringsbolaget Skandia Omsesidigt reduced its stake in Regeneron Pharmaceuticals by 92.3%, owning only 872 shares after selling 10,460 shares, which were worth $457,000 at the end of the reporting period.
• Regeneron Pharmaceuticals reported a strong earnings performance with an EPS of $12.89 for the quarter, surpassing estimates and achieving a 3.6% year-over-year revenue increase.
• The company recently declared a quarterly dividend of $0.88 per share, translating to an annual yield of 0.6% and a payout ratio of 8.87%.

Livforsakringsbolaget Skandia Omsesidigt trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 92.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 872 shares of the biopharmaceutical company's stock after selling 10,460 shares during the period. Livforsakringsbolaget Skandia Omsesidigt's holdings in Regeneron Pharmaceuticals were worth $457,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of REGN. GAMMA Investing LLC grew its position in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after buying an additional 814,713 shares during the last quarter. Nuveen LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $343,764,000. Pacer Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after purchasing an additional 390,374 shares during the period. Assenagon Asset Management S.A. boosted its stake in Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after purchasing an additional 303,785 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $127,215,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent research reports. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Morgan Stanley reiterated an "overweight" rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Finally, UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $6.72 during mid-day trading on Friday, hitting $591.99. 2,177,965 shares of the company's stock traded hands, compared to its average volume of 914,839. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm's 50 day simple moving average is $567.77 and its 200 day simple moving average is $575.13. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,154.56. The company has a market cap of $62.74 billion, a PE ratio of 14.92, a price-to-earnings-growth ratio of 1.98 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the firm posted $11.56 EPS. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.